← Back to Clinical Trials
Recruiting NCT04731246

NCT04731246 Video-oculography and Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04731246
Status Recruiting
Phase
Sponsor Association de Recherche Bibliographique pour les Neurosciences
Condition Parkinson Disease, Idiopathic
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2021-07-07
Primary Completion 2032-01

Trial Parameters

Condition Parkinson Disease, Idiopathic
Sponsor Association de Recherche Bibliographique pour les Neurosciences
Study Type INTERVENTIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-07-07
Completion 2032-01
Interventions
Video-oculography / Neuropsychological evaluations

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015): * the evolution of oculomotricity markers over time. * the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years. * the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography. * the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.

Eligibility Criteria

\*Inclusion Criteria: 1. Male or Female; 2. Clinically defined idiopathic Parkinson's Disease (PD); 3. Brain MRI performed in routine care in the 12 months preceding inclusion; 4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation; 5. Hoehn \& Yahr score: 1 to 3; 6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted); 7. Neuro-cognitive disorders: absent or minor (according to DSM5); 8. Sufficient written and oral expression in French; 9. Covered by a health insurance system; 10. Written informed consent signed by the patient; 11. Presence of a caregiver. \* Exclusion Criteria: 12. Psychiatric comorbidity (except anxiety or mild to moderate depression); 13. Neurological comorbidity, if significant; 14. Brain MRI showing: 1. significant cerebrovascular pathology (Fazekas I admitted), 2. another brain disease, including stroke. 15. Major cognitiv

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology